The principals of AcheRx LLC initially identified a development candidate for treatment of migraine and neuropathic pain and went on to accomplished in vivo proof-of-concept in rat models for migraine and nociception. Also worked on a peptide with improved potency, and extended duration of action, over previous peptide and small molecule clinical candidate and went onto tackle development of an extended-release formulation with evaluation also for non-addictive pain usage. The firm received SBIR funding for development of an extended-release formulation in fall 2021 with the clinical candidate being reported as having nbeen chosen by NIH for evaluation in the non-addictive pain program - but not record of follow-on funding.
